Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 509

1.

Expression of circular RNA CDR1‑AS in colon cancer cells increases cell surface PD‑L1 protein levels.

Tanaka E, Miyakawa Y, Kishikawa T, Seimiya T, Iwata T, Funato K, Odawara N, Sekiba K, Yamagami M, Suzuki T, Ishibashi R, Otsuka M, Koike K.

Oncol Rep. 2019 Oct;42(4):1459-1466. doi: 10.3892/or.2019.7244. Epub 2019 Jul 19.

PMID:
31322270
2.

[Rituximab for treatment of immune thrombocytopenia and thrombotic thrombocytopenic purpura].

Miyakawa Y.

Rinsho Ketsueki. 2019;60(5):480-487. doi: 10.11406/rinketsu.60.480. Japanese.

PMID:
31168017
3.

Challenges in management of unusual acquired factor V deficiency: A case report.

Takemoto K, Hamada O, Kitamura K, Fujiwara N, Miyakawa Y.

Medicine (Baltimore). 2019 Apr;98(17):e15259. doi: 10.1097/MD.0000000000015259.

4.

Language delay and developmental catch-up would be a clinical feature of pseudohypoparathyroidism type 1A during childhood.

Miyakawa Y, Takasawa K, Matsubara Y, Ihara K, Ohtsu Y, Kamasaki H, Kitsuda K, Kobayashi H, Satoh M, Sano S, Dateki S, Mochizuki H, Yokota I, Hasegawa Y, Kashimada K.

Endocr J. 2019 Mar 28;66(3):215-221. doi: 10.1507/endocrj.EJ18-0326. Epub 2019 Jan 23.

5.

Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease.

Arihiro S, Nakashima A, Matsuoka M, Suto S, Uchiyama K, Kato T, Mitobe J, Komoike N, Itagaki M, Miyakawa Y, Koido S, Hokari A, Saruta M, Tajiri H, Matsuura T, Urashima M.

Inflamm Bowel Dis. 2019 May 4;25(6):1088-1095. doi: 10.1093/ibd/izy346.

6.

Comparison of neurodevelopmental outcomes between monochorionic and dichorionic twins with birth weight ≤ 1500 g in Japan: a register-based cohort study.

Ichinomiya K, Maruyama K, Koizumi A, Inoue F, Fukuda K, Kaburagi K, Miyakawa Y; Neonatal Research Network of Japan.

J Perinatol. 2018 Oct;38(10):1407-1413. doi: 10.1038/s41372-018-0190-z. Epub 2018 Aug 6.

PMID:
30082774
7.

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.

Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23.

8.

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.

Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.

9.

Total body irradiation for hematopoietic stem cell transplantation during early childhood is associated with the risk for diabetes mellitus.

Nakagawa R, Hosokawa-Tsuji A, Aoki Y, Takasawa K, Maru M, Nakajima K, Sutani A, Miyakawa Y, Tomizawa D, Kashimada K, Morio T.

Endocrine. 2018 Jul;61(1):76-82. doi: 10.1007/s12020-018-1595-3. Epub 2018 Apr 24.

PMID:
29691808
10.

Agraphia with reversible splenial corpus callosum lesion caused by hypoglycemia.

Miyakawa Y, Fuchigami T, Aoki M, Mine Y, Suzuki J, Urakami T, Takahashi S.

Brain Dev. 2018 Aug;40(7):592-595. doi: 10.1016/j.braindev.2018.03.003. Epub 2018 Mar 30.

PMID:
29606344
11.

TTP and aHUS: new insights.

Miyakawa Y.

Rinsho Ketsueki. 2017;58(5):530-536. doi: 10.11406/rinketsu.58.530. Japanese.

PMID:
28592771
12.

Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan.

Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y, Higasa S, Moriki T, Yagi H, Miyata T, Murata M; For TTP group of Blood Coagulation Abnormalities Research Team, Research on Rare and Intractable Disease supported by Health, Labour, and Welfare Sciences Research Grants.

Int J Hematol. 2017 Jul;106(1):3-15. doi: 10.1007/s12185-017-2264-7. Epub 2017 May 26.

PMID:
28550351
13.

Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome.

Yamada Y, Abe R, Okano Y, Miyakawa Y.

Intern Med. 2017;56(9):1085-1088. doi: 10.2169/internalmedicine.56.7862. Epub 2017 May 1.

14.

Molecular mechanisms of insulin resistance in 2 cases of primary insulin receptor defect-associated diseases.

Tsuji-Hosokawa A, Takasawa K, Nomura R, Miyakawa Y, Numakura C, Hijikata A, Shirai T, Ogawa Y, Kashimada K, Morio T.

Pediatr Diabetes. 2017 Dec;18(8):917-924. doi: 10.1111/pedi.12508. Epub 2017 Feb 9.

PMID:
28181734
15.

Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.

Abe T, Sasaki A, Ueda T, Miyakawa Y, Ochiai H.

Medicine (Baltimore). 2017 Feb;96(6):e6056. doi: 10.1097/MD.0000000000006056.

16.

Exciting investigator-initiated clinical trials.

Miyakawa Y.

Rinsho Ketsueki. 2016;57(10):2145-2150. Japanese.

PMID:
27795524
17.

Malignant Hypertension with Thrombotic Microangiopathy.

Mitaka H, Yamada Y, Hamada O, Kosaka S, Fujiwara N, Miyakawa Y.

Intern Med. 2016;55(16):2277-80. doi: 10.2169/internalmedicine.55.6332. Epub 2016 Aug 15.

18.

Clinical guides for atypical hemolytic uremic syndrome in Japan.

Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan.

Pediatr Int. 2016 Jul;58(7):549-55. doi: 10.1111/ped.13044.

PMID:
27460397
19.

Clinical guides for atypical hemolytic uremic syndrome in Japan.

Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan.

Clin Exp Nephrol. 2016 Aug;20(4):536-543. doi: 10.1007/s10157-016-1276-6.

PMID:
27422619
20.

Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy.

Miyakawa Y, Imada K, Ichinohe T, Nishio K, Abe T, Murata M, Ueda Y, Fujimura Y, Matsumoto M, Okamoto S.

Int J Hematol. 2016 Aug;104(2):228-35. doi: 10.1007/s12185-016-2019-x. Epub 2016 May 17.

PMID:
27188338
21.

Fibrocalculous pancreatic diabetes in a Japanese girl with severe motor and intellectual disabilities.

Takasawa K, Miyakawa Y, Masamune A, Kashimada K, Shimohira M.

Acta Diabetol. 2016 Jun;53(3):507-10. doi: 10.1007/s00592-015-0834-9. Epub 2016 Jan 18. No abstract available.

PMID:
26782097
22.

PIAS3 enhances the transcriptional activity of HIF-1α by increasing its protein stability.

Nakagawa K, Kohara T, Uehata Y, Miyakawa Y, Sato-Ueshima M, Okubo N, Asaka M, Takeda H, Kobayashi M.

Biochem Biophys Res Commun. 2016 Jan 15;469(3):470-6. doi: 10.1016/j.bbrc.2015.12.047. Epub 2015 Dec 15.

PMID:
26697750
23.

Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.

Miyakawa Y, Katsutani S, Yano T, Nomura S, Nishiwaki K, Tomiyama Y, Higashihara M, Shirasugi Y, Nishikawa M, Ozaki K, Abe T, Kikuchi K, Kanakura Y, Fujimura K, Ikeda Y, Okamoto S.

Int J Hematol. 2015 Dec;102(6):654-61.

PMID:
26466831
24.

[Consensus report on the management of immune thrombocytopenia in pregnancy].

Miyakawa Y.

Rinsho Ketsueki. 2015 Oct;56(10):2086-91. doi: 10.11406/rinketsu.56.2086. Japanese.

PMID:
26458448
25.

A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.

Matsumoto K, Takayama N, Aisa Y, Ueno H, Hagihara M, Watanabe K, Nakaya A, Chen K, Shimizu T, Tsukada Y, Yamada Y, Nakazato T, Ishida A, Miyakawa Y, Yokoyama K, Nakajima H, Masuda Y, Yano T, Okamoto S; Keio BRB Study Group.

Int J Hematol. 2015 Jun;101(6):554-62. doi: 10.1007/s12185-015-1767-3. Epub 2015 Mar 19.

PMID:
25783753
26.

Estimated numbers of patients with liver disease related to hepatitis B or C virus infection based on the database reconstructed from medical claims from 2008 to 2010 in Japan.

Ohisa M, Kimura Y, Matsuo J, Akita T, Sato T, Matsuoka T, Sakamune K, Katayama K, Huy Do S, Miyakawa Y, Tanaka J.

Hepatol Res. 2015 Dec;45(12):1228-40. doi: 10.1111/hepr.12497. Epub 2015 Feb 26.

PMID:
25627814
27.

Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.

Kikuchi K, Miyakawa Y, Ikeda S, Sato Y, Takebayashi T.

BMC Health Serv Res. 2015 Jan 22;15:2. doi: 10.1186/s12913-015-0681-y.

28.

Analysis of the essentiality of ROM2 genes in the pathogenic yeasts Candida glabrata and Candida albicans using temperature-sensitive mutants.

Kanno T, Takekawa D, Miyakawa Y.

J Appl Microbiol. 2015 Apr;118(4):851-63. doi: 10.1111/jam.12745. Epub 2015 Feb 8.

29.

Hepatitis B virus infection in hemodialysis patients in Japan: Prevalence, incidence and occult hepatitis B virus infection.

Katayama K, Sato T, Do SH, Yamada H, Tabuchi A, Komiya Y, Matsuo J, Nakashima A, Ohisa M, Akita T, Yorioka N, Miyakawa Y, Yoshizawa H, Tanaka J.

Hepatol Res. 2015 Dec;45(12):1211-9. doi: 10.1111/hepr.12492. Epub 2015 Feb 19.

PMID:
25599580
30.

[Consensus report for the management of pregnancy with primary immune thrombocytopenia].

Miyakawa Y, Kashiwagi H, Takafuta T, Fujimura K, Kurata Y, Kobayashi T, Kimura T, Adachi T, Watanabe T, Imaizumi M, Takahashi Y, Matsubara K, Terui K, Kuwana M, Kanagawa T, Murata M, Tomiyama Y; Committee for clinical practice guide of primary immune thrombocytopenia in pregnancy.

Rinsho Ketsueki. 2014 Aug;55(8):934-47. Review. Japanese. No abstract available.

PMID:
25186483
31.

Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia.

Kanakura Y, Miyakawa Y, Wilde P, Smith J, Achenbach H, Okamoto S.

Int J Hematol. 2014 Oct;100(4):353-60. doi: 10.1007/s12185-014-1631-x. Epub 2014 Aug 27.

PMID:
25160063
32.

[Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: IV. Recent topics; 2. Rituximab for ITP and TTP].

Miyakawa Y.

Nihon Naika Gakkai Zasshi. 2014 Jul 10;103(7):1654-9. Japanese. No abstract available.

PMID:
25154261
33.

Seroprevalence, genotypic distribution and potential risk factors of hepatitis B and C virus infections among adults in Siem Reap, Cambodia.

Yamada H, Fujimoto M, Svay S, Lim O, Hok S, Goto N, Ohisa M, Akita T, Matsuo J, Do SH, Katayama K, Miyakawa Y, Tanaka J.

Hepatol Res. 2015 Apr;45(4):480-7. doi: 10.1111/hepr.12367. Epub 2014 Jul 7.

PMID:
24905888
34.

Successful treatment of severe lung hemorrhage caused by acquired factor V inhibitor with rituximab.

Yamada Y, Miyakawa Y, Sawano M, Okano Y.

Intern Med. 2014;53(10):1083-5.

35.

High prevalences of hepatitis B and C virus infections among adults living in Binh Thuan province, Vietnam.

Do SH, Yamada H, Fujimoto M, Ohisa M, Matsuo J, Akita T, Katayama K, Van Nguyen N, Miyakawa Y, Tanaka J.

Hepatol Res. 2015 Mar;45(3):259-68. doi: 10.1111/hepr.12350. Epub 2014 Jun 9.

PMID:
24799322
36.

Estimating numbers of persons with persistent hepatitis B virus infection transmitted vertically and horizontally in the birth cohort during 1950-1985 in Japan.

Sato T, Do SH, Asao T, Akita T, Katayama K, Tatara K, Miyakawa Y, Tanaka J.

Hepatol Res. 2014 Oct;44(10):E181-8. doi: 10.1111/hepr.12288. Epub 2014 Jan 22.

PMID:
24308776
37.

The mandibular response to occlusal relief using a flat guidance splint.

Reichardt G, Miyakawa Y, Otsuka T, Sato S.

Int J Stomatol Occlusion Med. 2013;6:134-139. Epub 2013 Sep 17.

38.

[A case of blastic plasmacytoid dendritic cell neoplasm involving the skin].

Fukuoka S, Miyakawa Y, Suzuki T, Irie R, Kurihara Y, Okano H, Akizuki S.

Gan To Kagaku Ryoho. 2013 Sep;40(9):1255-8. Japanese.

PMID:
24047792
39.

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.

Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, Hattori T, Katsura K, Kanakura Y.

Int J Hematol. 2013 Sep;98(3):323-30. doi: 10.1007/s12185-013-1401-1. Epub 2013 Jul 30.

PMID:
23896965
40.

Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.

Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.

J Gastroenterol. 2014 Mar;49(3):538-46. doi: 10.1007/s00535-013-0821-2. Epub 2013 Jun 20.

PMID:
23783839
41.

Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.

Miyazaki O, Sekine K, Nakajima N, Ichimura E, Ebara K, Nagai D, Onda T, Miyakawa Y, Okamoto K, Morino T.

Int J Cancer. 2014 Jan 1;134(1):218-23. doi: 10.1002/ijc.28333. Epub 2013 Jul 16.

43.

Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan.

Akita T, Ohisa M, Kimura Y, Fujimoto M, Miyakawa Y, Tanaka J.

Hepatol Res. 2014 Jul;44(7):713-9. doi: 10.1111/hepr.12177. Epub 2013 Jul 11.

PMID:
23730747
44.

High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B.

Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, Mizokami M, Miyakawa Y, Koike K.

Clin Infect Dis. 2013 Oct;57(7):935-42. doi: 10.1093/cid/cit348. Epub 2013 May 23.

PMID:
23704123
45.

[Current management of primary immune thrombocytopenia in Japan].

Miyakawa Y.

Rinsho Ketsueki. 2013 Apr;54(4):350-6. Review. Japanese. No abstract available.

PMID:
23666216
46.

Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.

Okamoto S, Miyakawa Y, Smith J, Hodgson I, Abhyankar B, Troy S, Kanakura Y.

Int J Hematol. 2013 Mar;97(3):360-8. doi: 10.1007/s12185-013-1265-4. Epub 2013 Feb 3.

PMID:
23378182
47.

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.

Bae SK, Yatsuhashi H, Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, Abiru S, Komori A, Migita K, Nakamura M, Ito M, Miyakawa Y, Ishibashi H.

Med Sci Monit. 2012 Dec;18(12):CR698-705.

48.

[Reference guide for management of adult idiopathic thrombocytopenic purpura (ITP) 2012 version].

Fujimura K, Miyakawa Y, Kurata Y, Kuwana M, Tomiyama Y, Murata M.

Rinsho Ketsueki. 2012 Apr;53(4):433-42. Review. Japanese. No abstract available.

PMID:
22687977
49.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.

J Clin Virol. 2012 Aug;54(4):352-4. doi: 10.1016/j.jcv.2012.04.024. Epub 2012 Jun 1.

PMID:
22658798
50.

Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma.

Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, Miyakawa Y, Nishino H, Tajiri H.

Med Oncol. 2012 Dec;29(4):2800-8. doi: 10.1007/s12032-012-0220-1. Epub 2012 Mar 30.

PMID:
22460836

Supplemental Content

Loading ...
Support Center